This should be distinguished from dopamine agonist resistance, which is preferred when there is failure to normalize serum prolactin and/or achieve significant tumor shrinkage (in macroprolactinomas) despite good tolerance and concordance with standard clinical dosages [17, 18]. Here, PRL is linked to neoplasm.